{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:38:41Z","timestamp":1789191521191,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,8,7]],"date-time":"2013-08-07T00:00:00Z","timestamp":1375833600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s40263-013-0091-9","type":"journal-article","created":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T08:22:25Z","timestamp":1375777345000},"page":"817-827","source":"Crossref","is-referenced-by-count":33,"title":["Systematic Review and Meta-Analysis of the Efficacy and Safety of Perampanel in the Treatment of Partial-Onset Epilepsy"],"prefix":"10.1007","volume":"27","author":[{"given":"Warrington W. Q.","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. W.","family":"Sing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Worsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C. K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,7]]},"reference":[{"issue":"13","key":"91_CR1","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMra022308","volume":"349","author":"BS Chang","year":"2003","unstructured":"Chang BS, Lowenstein DH. Epilepsy. N Engl J Med. 2003;349(13):1257\u201366.","journal-title":"N Engl J Med"},{"key":"91_CR2","unstructured":"World Health Organization. Fact sheets-epilepsy. 2012. http:\/\/www.who.int\/mediacentre\/factsheets\/fs999\/en\/index.html . Accessed 27 Feb 2013."},{"key":"91_CR3","unstructured":"National Institute for Health and Clinical Excellence. CG137 epilepsy: NICE guidance. 2012. http:\/\/guidance.nice.org.uk\/CG137\/NICEGuidance\/pdf\/English . Accessed 27 Feb 2013."},{"issue":"8","key":"91_CR4","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000123695.22623.32","volume":"62","author":"JA French","year":"2004","unstructured":"French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62(8):1261\u201373.","journal-title":"Neurology."},{"issue":"2","key":"91_CR5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1734-1140(11)70497-2","volume":"63","author":"W Lason","year":"2011","unstructured":"Lason W, Dudra-Jastrzebska M, Rejdak K, Czuczwar SJ. Basic mechanisms of antiepileptic drugs and their pharmacokinetic\/pharmacodynamic interactions: an update. Pharmacological reports PR. 2011;63(2):271\u201392.","journal-title":"Pharmacological reports PR."},{"issue":"4","key":"91_CR6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.neuint.2012.02.035","volume":"61","author":"L Ceolin","year":"2012","unstructured":"Ceolin L, Bortolotto ZA, Bannister N, Collingridge GL, Lodge D, Volianskis A. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int. 2012;61(4):517\u201322.","journal-title":"Neurochem Int"},{"issue":"2","key":"91_CR7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5698\/1535-7511-11.2.56","volume":"11","author":"MA Rogawski","year":"2011","unstructured":"Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr Am Epilepsy Soc. 2011;11(2):56\u201363.","journal-title":"Epilepsy Curr Am Epilepsy Soc"},{"issue":"2","key":"91_CR8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1586\/ern.12.154","volume":"13","author":"V Shvarts","year":"2013","unstructured":"Shvarts V, Chung S. Perampanel: newly approved, novel antiepileptic medication for partial-onset seizures. Exp Rev Neurother. 2013;13(2):131\u20134.","journal-title":"Exp Rev Neurother"},{"issue":"1","key":"91_CR9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2012.06.005","volume":"103","author":"L Gao","year":"2013","unstructured":"Gao L, Xia L, Zhao FL, Li SC. Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: a meta-analysis of randomized placebo-controlled trials. Epilepsy Res. 2013;103(1):31\u201344.","journal-title":"Epilepsy Res"},{"issue":"1","key":"91_CR10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0404.2011.01588.x","volume":"125","author":"GL Krauss","year":"2012","unstructured":"Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurologica Scandinavica. 2012;125(1):8\u201315.","journal-title":"Acta Neurologica Scandinavica"},{"issue":"6","key":"91_CR11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","volume":"79","author":"JA French","year":"2012","unstructured":"French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79(6):589\u201396.","journal-title":"Neurology."},{"issue":"1","key":"91_CR12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","volume":"54","author":"JA French","year":"2013","unstructured":"French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54(1):117\u201325.","journal-title":"Epilepsia."},{"issue":"18","key":"91_CR13","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","volume":"78","author":"GL Krauss","year":"2012","unstructured":"Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408\u201315.","journal-title":"Neurology."},{"key":"91_CR14","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"key":"91_CR15","doi-asserted-by":"crossref","unstructured":"ILAE. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1981;22(4):489\u2013501.","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"91_CR16","unstructured":"European Medicines Agency. Clinical investigation of medicinal products in the treatment of epileptic disorders. 2010. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070043.pdf . Accessed 27 Feb 2013."},{"issue":"7","key":"91_CR17","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1528-1167.2007.01136.x","volume":"48","author":"DM Gazzola","year":"2007","unstructured":"Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia. 2007;48(7):1303\u20137.","journal-title":"Epilepsia."},{"key":"91_CR18","unstructured":"Higgins JP, Altman DG, Sterne JA. Chapter 8: assessing risk of bias in included studies. 2011. http:\/\/www.cochrane.org\/sites\/default\/files\/uploads\/handbook\/Handbook510pdf_Ch08_RiskOfBias.pdf . Accessed 12 March 2013."},{"issue":"6","key":"91_CR19","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/0272989X05282643","volume":"25","author":"AE Ades","year":"2005","unstructured":"Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Mak Int J Soc Med Decis Mak. 2005;25(6):646\u201354.","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"issue":"2","key":"91_CR20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97\u2013111.","journal-title":"Res Synth Methods."},{"key":"91_CR21","unstructured":"Eisai Inc. Prescribing information of Fycompa. 2012. http:\/\/us.eisai.com\/package_inserts\/FycompaPI.pdf . Accessed 27 Feb 2013."},{"issue":"9","key":"91_CR22","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.seizure.2012.07.011","volume":"21","author":"M Martyn-St James","year":"2012","unstructured":"Martyn-St James M, Glanville J, McCool R, Duffy S, Cooper J, Hugel P, et al. The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison. Seizure J Brit Epilepsy Assoc. 2012;21(9):665\u201378.","journal-title":"Seizure J Brit Epilepsy Assoc."},{"issue":"5","key":"91_CR23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.seizure.2007.12.003","volume":"17","author":"G Zaccara","year":"2008","unstructured":"Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure J Brit Epilepsy Assoc. 2008;17(5):405\u201321.","journal-title":"Seizure J Brit Epilepsy Assoc"},{"issue":"1","key":"91_CR24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1528-1167.2012.03648.x","volume":"54","author":"GL Krauss","year":"2013","unstructured":"Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Squillacote D, et al. Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia. 2013;54(1):126\u201334.","journal-title":"Epilepsia."},{"issue":"10","key":"91_CR25","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1528-1157.1999.tb02017.x","volume":"40","author":"ICK Wong","year":"1999","unstructured":"Wong ICK, Chadwick DW, Fenwick PBC, Mawer GE, Sander JWAS. The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. Epilepsia. 1999;40(10):1439\u201345.","journal-title":"Epilepsia."},{"issue":"9566","key":"91_CR26","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","volume":"369","author":"AG Marson","year":"2007","unstructured":"Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1016\u201326.","journal-title":"Lancet."},{"issue":"10","key":"91_CR27","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1046\/j.1528-1157.2001.02101.x","volume":"42","author":"IC Wong","year":"2001","unstructured":"Wong IC, Mawer GE, Sander JW, Lhatoo SD. A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy. Epilepsia. 2001;42(10):1354\u20138.","journal-title":"Epilepsia."},{"issue":"6","key":"91_CR28","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2125.2006.02842.x","volume":"63","author":"R Ackers","year":"2007","unstructured":"Ackers R, Murray ML, Besag FM, Wong IC. Prioritizing children\u2019s medicines for research: a pharmaco-epidemiological study of antiepileptic drugs. Brit J Clin Pharmacol. 2007;63(6):689\u201397.","journal-title":"Brit J Clin Pharmacol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-013-0091-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0091-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0091-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T02:43:59Z","timestamp":1715827439000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-013-0091-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,7]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["91"],"URL":"https:\/\/doi.org\/10.1007\/s40263-013-0091-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,7]]}}}